Prostatitis secondary prevention

Jump to: navigation, search
Urinary Tract Infections Main Page

Prostatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Prostatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT scan

Echocardiography and Ultrasound

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Prostatitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Prostatitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Prostatitis secondary prevention

CDC on Prostatitis secondary prevention

Prostatitis secondary prevention in the news

Blogs on Prostatitis secondary prevention

Directions to Hospitals Treating Prostatitis

Risk calculators and risk factors for Prostatitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

Secondary preventive therapies struggle due to developing resistance in the strains causing prostatitis. Fosfomycin given before urogenital procedures is helpful in preventing prostatitis. Ginsenoid has a preventive effect on chronic bacterial prostatitis but some still consider it controversial due to lack of evidence.[1]

Secondary Prevention

The following facts about secondary prevention of prostatitis must be kept in mind[2][3]

  • Due to resistant strains, empiric antibiotics are not as effective in preventing episodes of prostatitis.
  • Fosfomycin has bee used prophylactically in patients undergoing TURP.
  • Ginsenoid is effective in preventing chronic bacterial prostatitis.

References

  1. Sang Hoon Kim, U.-Syn Ha, Dong Wan Sohn, Seung-Ju Lee, Hyun Woo Kim, Chang Hee Han & Yong-Hyun Cho (2012). "Preventive effect of ginsenoid on chronic bacterial prostatitis". Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 18 (5): 709–714. doi:10.1007/s10156-012-0406-7. PMID 22450878. Unknown parameter |month= ignored (help)
  2. Sang Hoon Kim, U.-Syn Ha, Dong Wan Sohn, Seung-Ju Lee, Hyun Woo Kim, Chang Hee Han & Yong-Hyun Cho (2012). "Preventive effect of ginsenoid on chronic bacterial prostatitis". Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 18 (5): 709–714. doi:10.1007/s10156-012-0406-7. PMID 22450878. Unknown parameter |month= ignored (help)
  3. B. J. Gardiner, A. A. Mahony, A. G. Ellis, N. Lawrentschuk, D. M. Bolton, P. T. Zeglinski, A. G. Frauman & M. L. Grayson (2014). "Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 58 (4): e101–e105. doi:10.1093/cid/cit704. PMID 24170195. Unknown parameter |month= ignored (help)

Linked-in.jpg